Korean J Urol.  2011 Jun;52(6):373-378.

Prostatic Disease and Sexual Dysfunction

• Kim SW

Abstract

Prostatitis and benign prostatic hyperplasia (BPH) are common prostatic diseases. Furthermore, the incidence of prostate cancer has recently shown a rapid increase, even in Korea. Pain caused by prostatitis may induce sexual dysfunction, including erectile dysfunction and ejaculatory disturbance. And BPH itself, or treatments for BPH, may affect sexual function. In addition, with increased detection of localized prostate cancer, surgical treatments and radiation therapy have also increased, and the treatments may cause sexual dysfunction. Aging is also an important factor in the deterioration of the quality of life of men. Deterioration of quality of life caused by prostate diseases may be affected not only by the prostate diseases themselves but also by the sexual dysfunction caused by the prostate diseases secondarily. Thus, consideration of these points at the time of treatment of prostate disease is required. Therapies suitable to each condition should be selected with an understanding of the close association of prostate diseases and associated sexual dysfunction with the quality of life of males.

Keyword

Erectile dysfunction; Prostatic hyperplasia; Prostatic neoplasms; Prostatitis

MeSH Terms

Aging
Erectile Dysfunction
Humans
Incidence
Korea
Male
Prostate
Prostatic Diseases
Prostatic Hyperplasia
Prostatic Neoplasms
Prostatitis
Quality of Life

Reference

1. Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR, et al. Rising prostate cancer rates in South Korea. Prostate. 2006. 66:1285–1291.

2. Yong DJ, Lee KC, Cho IR. The effect of lower urinary tract symptoms on erectile function and the frequency of sexual intercourse. Korean J Urol. 2007. 48:458–462.

3. Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "Aging Male" symptoms? Results of the "Cologne Male Survey". Eur Urol. 2003. 44:588–594.

4. Chung WS, Nehra A, Jacobson DJ, Roberts RO, Rhodes T, Girman CJ, et al. Lower urinary tract symptoms and sexual dysfunction in community-dwelling men. Mayo Clin Proc. 2004. 79:745–749.

5. Cha JS, Park JK. Association between lower urinary tract symptoms and erectile dysfunction. Korean J Urol. 2005. 46:1023–1027.

6. Burger B, Weidner W, Altwein JE. Prostate and sexuality: an overview. Eur Urol. 1999. 35:177–184.

7. Collins MM, Stafford RS, O'Leary MP, Barry MJ. How common is prostatitis? A national survey of physician visits. J Urol. 1998. 159:1224–1228.

8. Wiygul RD. Prostatitis: epidemiology of inflammation. Curr Urol Rep. 2005. 6:282–289.

9. Krieger JN. Classification, epidemiology, and implications of chronic prostatitis in North America, Europe and Asia. Minerva Urol Nefrol. 2004. 56:99–107.

10. Liang CZ, Zhang XJ, Hao ZY, Shi HQ, Wang KX. Prevalence of sexual dysfunction in Chinese men with chronic prostatitis. BJU Int. 2004. 93:568–570.

11. Lutz MC, Roberts RO, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ. Cross-sectional associations of urogenital pain and sexual function in a community based cohort of older men: olmsted county, Minnesota. J Urol. 2005. 174:624–628.

12. Brown AJ. Ciprofloxacin as cure of premature ejaculation. J Sex Marital Ther. 2000. 26:351–352.

13. El-Nashaar A, Shamloul R. Antibiotic treatment can delay ejaculation in patients with premature ejaculation and chronic bacterial prostatitis. J Sex Med. 2007. 4:491–496.

14. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984. 132:474–479.

15. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999. 281:537–544.

16. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, Rodriguez-Vela L, Jimenez-Cruz JF, Burgos-Rodriguez R. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol. 2001. 166:569–574.

17. Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs R, Fourcade R, et al. The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study. BJU Int. 2003. 92:719–725.

18. Blanker MH, Bosch JL, Groeneveld FP, Bohnen AM, Prins A, Thomas S, et al. Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: prevalence, concern, and relation to sexual activity. Urology. 2001. 57:763–768.

19. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003. 44:637–649.

20. Andersson KE. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol. 2002. 19:390–396.

21. Kester RR, Mooppan UM, Gousse AE, Alver JE, Gintautas J, Gulmi FA, et al. Pharmacological characterization of isolated human prostate. J Urol. 2003. 170:1032–1038.

22. Burnett AL, Maguire MP, Chamness SL, Ricker DD, Takeda M, Lepor H, et al. Characterization and localization of nitric oxide synthase in the human prostate. Urology. 1995. 45:435–439.

23. Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H. Effects of nitric oxide on human and canine prostates. Urology. 1995. 45:440–446.

24. Andersson KE. Erectile physiological and pathophysiological pathways involved in erectile dysfunction. J Urol. 2003. 170:S6–S13.

25. Hurt KJ, Musicki B, Palese MA, Crone JK, Becker RE, Moriarity JL, et al. Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection. Proc Natl Acad Sci USA. 2002. 99:4061–4066.

26. Price DT, Schwinn DA, Lomasney JW, Allen LF, Caron MG, Lefkowitz RJ. Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. J Urol. 1993. 150:546–551.

27. Walden PD, Gerardi C, Lepor H. Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J Urol. 1999. 161:635–640.

28. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev. 1995. 75:191–236.

29. Reilly CM, Stopper VS, Mills TM. Androgens modulate the alpha-adrenergic responsiveness of vascular smooth muscle in the corpus cavernosum. J Androl. 1997. 18:26–31.

30. Wettschureck N, Offermanns S. Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med. 2002. 80:629–638.

31. Rees RW, Foxwell NA, Ralph DJ, Kell PD, Moncada S, Cellek S. Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol. 2003. 170:2517–2522.

32. Büyükafşar K, Levent A, Ark M. Expression of Rho-kinase and its functional role in the contractile activity of the mouse vas deferens. Br J Pharmacol. 2003. 140:743–749.

33. Chitaley K, Wingard CJ, Clinton Webb R, Branam H, Stopper VS, Lewis RW, et al. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med. 2001. 7:119–122.

34. Chitaley K, Bivalacqua TJ, Champion HC, Usta MF, Hellstrom WJ, Mills TM, et al. Adeno-associated viral gene transfer of dominant negative RhoA enhances erectile function in rats. Biochem Biophys Res Commun. 2002. 298:427–432.

35. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000. 87:840–844.

36. Barton M, Cosentino F, Brandes RP, Moreau P, Shaw S, Lüscher TF. Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. Hypertension. 1997. 30:817–824.

37. Cho JJ, Cadet P, Salamon E, Mantione K, Stefano GB. The nongenomic protective effects of estrogen on the male cardiovascular system: clinical and therapeutic implications in aging men. Med Sci Monit. 2003. 9:RA63–RA68.

38. Bloch W, Klotz T, Loch C, Schmidt G, Engelmann U, Addicks K. Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate. 1997. 33:1–8.

39. Burnett AL, Calvin DC, Chamness SL, Liu JX, Nelson RJ, Klein SL, et al. Urinary bladder-urethral sphincter dysfunction in mice with targeted disruption of neuronal nitric oxide synthase models idiopathic voiding disorders in humans. Nat Med. 1997. 3:571–574.

40. Mevorach RA, Bogaert GA, Kogan BA. Role of nitric oxide in fetal lower urinary tract function. J Urol. 1994. 152:510–514.

41. Persson K, Igawa Y, Mattiasson A, Andersson KE. Effects of inhibition of the L-arginine/nitric oxide pathway in the rat lower urinary tract in vivo and in vitro. Br J Pharmacol. 1992. 107:178–184.

42. El-Alfy M, Luu-The V, Huang XF, Berger L, Labrie F, Pelletier G. Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology. 1999. 140:1481–1491.

43. Helgason AR, Adolfsson J, Dickman P, Fredrikson M, Arver S, Steineck G. Waning sexual function--the most important disease-specific distress for patients with prostate cancer. Br J Cancer. 1996. 73:1417–1421.

44. Karakiewicz PI, Aprikian AG, Bazinet M, Elhilali MM. Patient attitudes regarding treatment-related erectile dysfunction at time of early detection of prostate cancer. Urology. 1997. 50:704–709.

45. Mulhall JP, Secin FP, Guillonneau B. Artery sparing radical prostatectomy--myth or reality? J Urol. 2008. 179:827–831.

46. Secin FP, Touijer K, Mulhall J, Guillonneau B. Anatomy and preservation of accessory pudendal arteries in laparoscopic radical prostatectomy. Eur Urol. 2007. 51:1229–1235.

47. Müller A, Parker M, Waters BW, Flanigan RC, Mulhall JP. Penile rehabilitation following radical prostatectomy: predicting success. J Sex Med. 2009. 6:2806–2812.

48. Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT. Factors predicting recovery of erections after radical prostatectomy. J Urol. 2000. 164:1929–1934.

49. Ayyathurai R, Manoharan M, Nieder AM, Kava B, Soloway MS. Factors affecting erectile function after radical retropubic prostatectomy: results from 1620 consecutive patients. BJU Int. 2008. 101:833–836.

50. Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol. 2004. 172:2227–2231.

51. Eastham JA, Scardino PT, Kattan MW. Predicting an optimal outcome after radical prostatectomy: the trifecta nomogram. J Urol. 2008. 179:2207–2210.

52. Montorsi F, Briganti A, Salonia A, Rigatti P, Burnett AL. Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy. Eur Urol. 2004. 45:123–133.

53. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol. 2008. 53:68–80.

54. Namiki S, Ishidoya S, Tochigi T, Ito A, Arai Y. Quality of life after radical prostatectomy in elderly men. Int J Urol. 2009. 16:813–819.

55. Sandler HM, Dunn RL, McLaughlin PW, Hayman JA, Sullivan MA, Taylor JM. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2000. 48:629–633.

56. Incrocci L. Sexual function after external-beam radiotherapy for prostate cancer: what do we know? Crit Rev Oncol Hematol. 2006. 57:165–173.

57. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008. 358:1250–1261.

58. Kato T, Komiya A, Suzuki H, Imamoto T, Ueda T, Ichikawa T. Effect of androgen deprivation therapy on quality of life in Japanese men with prostate cancer. Int J Urol. 2007. 14:416–421.